You are here

  • Home
  • Archive
  • Volume 58, Issue 12
  • Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFα reduce colitis-associated colorectal carcinogenesis?

Article info

Article menu
Download PDFPDF
PostScript
Letter
Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFα reduce colitis-associated colorectal carcinogenesis?

Authors

  1. Correspondence to Dr L Biancone, Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy; biancone{at}med.uniroma2.it
View Full Text

Citation

Biancone L, Petruzziello C, Calabrese E, et al
Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFα reduce colitis-associated colorectal carcinogenesis?
Gut 2009;58:1703.

Publication history

  • First published November 18, 2009.
Online issue publication 
April 18, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

BMJ Publishing Group Ltd and British Society of Gastroenterology. All rights reserved.